Configure, sample and produce your supplement range in one place.
At a glance
- Format suitability
- Reviewed for gummies — confirmed per project.
Why brands use it
Why brands use CoQ10
CoQ10 is a formulation input reviewed per project, sitting in the other family. On DAT Supply briefs the positioning is set by the brand brief and reviewed against the target market’s claim rules — we do not pre-position an active for any single benefit. Editorial framing uses only EU 432/2012- or DSHEA-compatible wording — we never promote unauthorised claims, even when the active has consumer-side momentum. Format-wise we have considered CoQ10 for gummies; the per-format formulation notes below describe the live constraints (taste, payload, stability, packaging) we tune in the formulation pass. Sourcing form (extract ratio for botanicals, salt or chelate form for minerals, free-form vs ester for amino acids) is reviewed against the brief, with documentation matched to the target market’s import rules. Inclusion rate and claim wording are reviewed per project — we don’t publish off-the-shelf doses.
FormulationHow we use CoQ10 in formulas
A public-safe formulation reference — how this active behaves in our
formats, common pairings and handling notes. Final formulation, dose and
on-pack copy are confirmed per project.
- Heat stable
- Limited — use coated forms
- Soluble in matrix
- Conditional
- Vegan supply
- Project-specific
Claim wordingEU-authorised health claims
EU-authorised wording for this ingredient is reviewed per project against Reg. 1924/2006 and the authorised list under Reg. 432/2012. No final claim wording is implied by this page.
CoQ10 is reviewed against the target market’s claim posture: EU 432/2012 wording (UK tracks EU post-Brexit) for the EU/UK route, and DSHEA structure-function wording with the FDA disclosure for the US route. Pack copy is rewritten per market and confirmed per project.
EU-authorised health claims Authorised at ≥15% NRV per daily serving. Claim wording must appear verbatim on consumer packaging. DAT reviews final pack copy per project against EU 1924/2006 and the authorised list under EU 432/2012.
Serving
Typical serving and reference level
Where the serving level for CoQ10 is set, and who sets it. The
figure that reaches your label is fixed against the specification for your
formula and your market — not read off this page.
- Measured in
- mg
Reference level Typical anchor: mg per serving — confirmed per project.
CoQ10 is measured by weight (mg) per serving on DAT Supply briefs. The working anchor — the inclusion rate against which target-market claim wording is reviewed — is set during the formulation pass for each project rather than published as a fixed number on the public page. Final per-serving load depends on the chosen format (gummy payload window, capsule fill weight, softgel oil load, sachet or powder scoop size, oral-liquid bottle geometry) and the claim wording the brand needs to support against the target market. Sourcing form (extract ratio, standardised marker, micronised vs granular, salt or chelate form) is reviewed in the same pass. Country-level upper limits (France, Italy, Belgium for the EU; California Prop 65 for the US) are checked before any inclusion rate is finalised. Dose is confirmed per project — we don’t publish off-the-shelf dose tables for any active in the catalogue.
Research library
The evidence behind CoQ10
6 studies relevant to CoQ10, strongest
evidence first. Peer-reviewed sources and regulatory opinions. Citations only — DAT cites
the science, it does not endorse the publishers. Studies are on the ingredient, not on any
finished product.
CoQ10Peer-reviewed studyStrong evidence
Bioavailability of coenzyme Q10 supplements: a systematic review
- Population
- Healthy adults
- Studied dose
- 100-300 mg single dose
- Duration
- Single dose to 4 weeks
Systematic review of 20 studies found that solubilised forms (e.g., with d-limonene, liposomal) significantly increase absorption compared to crystalline ubiquinone.
CoQ10Meta-analysisStrong evidence
Coenzyme Q10 for heart failure
- Population
- Heart failure patients (NYHA II-IV)
- Studied dose
- 100-300 mg/day
- Duration
- 3-12 months
Meta-analysis of 14 RCTs (n=2149) found CoQ10 supplementation improved ejection fraction and reduced hospitalisations in heart failure patients.
CoQ10Peer-reviewed studyStrong evidence
Coenzyme Q10 in patients with heart failure: a systematic review and meta-analysis
- Population
- Heart failure patients (NYHA II-IV)
- Studied dose
- 100-300 mg/day
- Duration
- 3-12 months
Meta-analysis of 13 RCTs found CoQ10 supplementation improved ejection fraction and reduced mortality in heart failure patients.
CoQ10Peer-reviewed studyStrong evidence
Effect of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials
- Population
- Patients on statin therapy
- Studied dose
- 100-200 mg/day
- Duration
- 4-12 weeks
Meta-analysis of 6 RCTs showed CoQ10 supplementation reduced statin-induced muscle pain and weakness.
CoQ10Peer-reviewed studyModerate evidence
Effect of coenzyme Q10 on statin-induced myopathy: a meta-analysis
- Population
- Patients on statin therapy with myopathy
- Studied dose
- 100-200 mg/day
- Duration
- 4-12 weeks
Meta-analysis of 12 RCTs (n=302) showed CoQ10 supplementation reduced statin-induced muscle pain and improved muscle function.
CoQ10Peer-reviewed studyLimited evidence
Coenzyme Q10: a key antioxidant in the mitochondrial respiratory chain
- Population
- In vitro and animal models
- Studied dose
- Not applicable
- Duration
- Not applicable
Review detailing CoQ10's role as an electron carrier and antioxidant in mitochondria, protecting against lipid peroxidation.
The formulas above sit in these private-label ranges:
Adjacent actives
Ingredients that sit alongside this one
Start Build a formula around CoQ10
Explore the private-label options that use CoQ10 — review formula, format and packaging on each product before you commit.
